Molecular targets for breast cancer therapy and prevention (original) (raw)

• McPherson, K., Steel, C.M. & Dixon, J.M. ABC of breast diseases. Breast cancer epidemiology, risk factors, and genetics. Br. Med. J. 321, 624–628 (2000).
  Article CAS Google Scholar
• Greenlee, R.T., Murray, T., Bolden, S. & Wingo, P.A. Cancer statistics, 2000. CA Cancer J. Clin. 50, 7–33 (2000).
  Article CAS Google Scholar
• Saphner, T., Tormey, D.C. & Gray, R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 14, 2738–2746 (1996).
  Article CAS Google Scholar
• Hortobagyi, G.N. Developments in chemotherapy of breast cancer. Cancer 88, 3073–3079 (2000).
  Article CAS Google Scholar
• Carter, S.K. Single and combination nonhormonal chemotherapy in breast cancer. Cancer 30, 1543–1555 (1972).
  Article CAS Google Scholar
• Fossati, R, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. 16, 3439–3460 (1998).
  Article CAS Google Scholar
• Lanni, J.S., Lowe, S.W., Licitra, E.J., Liu, J.O. & Jacks, T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. USA 94, 9679–9683 (1997).
  Article CAS Google Scholar
• Peto, J. & Mack, T.M. High constant incidence in twins and other relatives of women with breast cancer Nature Genet. 26, 411–414 (2000).
  Article CAS Google Scholar
• Hortobagyi, G. Adjuvant therapy for breast cancer. Annu. Rev. Med. 51, 377–392 (2000).
  Article CAS Google Scholar
• Ullrich, A. et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418–425 (1984).
  Article CAS Google Scholar
• Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19, 6102–6114 (2000).
  Article CAS Google Scholar
• Hong, W.K. & Ullrich A.U. The role of EGFR in solid tumors and implication for therapy. Oncol. Biotherapeutics 1, 1–30 (2000).
  Google Scholar
• Cardiello, F. et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053–2063 (2000).
  Google Scholar
• Coussens, L. et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132–1139 (1985).
  Article CAS Google Scholar
• Slamon, D.J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
  Article CAS Google Scholar
• Baselga, J. Clinical trials of Herceptin (trastuzumab). Eur. J. Cancer 37, S18–24 (2001).
  Article CAS Google Scholar
• Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001)
  Article CAS Google Scholar
• Pietras, R.J. et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 59, 1347–1355 (1999).
  CAS PubMed Google Scholar
• Kurokawa, H. et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60, 5887–5894 (2000).
  CAS PubMed Google Scholar
• Lee, R.J. et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell Biol. 20, 672–683 (2000).
  Article CAS Google Scholar
• Pestell, R.G. et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrine Rev. 20, 501–534 (1999).
  CAS Google Scholar
• Sausville, E.A., Johnson, J., Alley, M., Zaharevitz, D. & Senderowicz, A.M. Inhibition of CDKs as a therapeutic modality. Ann. NY Acad. Sci. 910, 207–221 (2000).
  Article CAS Google Scholar
• Senderowicz, A.M. & Sausville, E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer. Inst. 92, 376–387 (2000).
  Article CAS Google Scholar
• Sliwkowski, M.X. et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26, 60–70 (1999).
  CAS Google Scholar
• Mazumdar, A. et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nature Cell Biol. 3, 30–37 (2001).
  Article CAS Google Scholar
• Yang, X. et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60, 6890–6894 (2000).
  CAS PubMed Google Scholar
• Richon, V.M., Sandhoff, T.W., Rifkind, R.A. & Marks, P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97, 10014–10019 (2000).
  Article CAS Google Scholar
• Huang, L. & Pardee, A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 6, 849–866 (2000).
  Article CAS Google Scholar
• Gayther, S.A. et al. Mutations truncating the EP300 acetylase in human cancers. Mutations truncating the EP300 acetylase in human cancers. Nature Genet. 24, 300–303 (2000).
  Article CAS Google Scholar
• Xing, X. et al. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nature Med. 6, 189–195 (2000).
  Article CAS Google Scholar
• Tazebay, U.H. et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nature Med. 6, 871–878 (2000).
  Article CAS Google Scholar
• Heffelfinger, S.C., Miller, M.A., Yassin, R. & Gear, R. Angiogenic growth factors in preinvasive breast disease. Clin Cancer Res. 5, 2867–2876 (1999).
  CAS PubMed Google Scholar
• Saaristo, A., Karpanen, T. & Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19, 6122–6129 (2000).
  Article CAS Google Scholar
• Boehm, T., Folkman, J., Browder, T. & O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404–407 (1997).
  Article CAS Google Scholar
• Kerbel, R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21, 505–515 (2000).
  Article CAS Google Scholar
• Millauer, B., Shawver, L.K., Plate, K.H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576–579 (1994).
  Article CAS Google Scholar
• Fong, T.A. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59, 99–106 (1999).
  CAS PubMed Google Scholar
• Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371–1388 (1998).
  Article CAS Google Scholar
• Gail, M.H. et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl. Cancer Inst. 91, 1829–1846 (1999).
  Article CAS Google Scholar
• Rosenbaum Smith, S.M. & Osborne, M.P. Breast cancer chemoprevention Am. J. Surg. 180, 249–251 (2000).
  Article CAS Google Scholar
• Torrisi, R. & Decensi, A. Fenretinide and cancer prevention. Curr. Oncol. Rep. 2, 263–270 (2000).
  Article CAS Google Scholar
• Yang, L.M., Tin- U C., Wu K. & Brown, P. Role of retinoid receptor in the prevention and treatment of breast cancer. J. Mammary Gland Biol. Neoplasia 4, 377–388 (1999).
  Article CAS Google Scholar
• Schiff, R. et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl. Cancer Inst. 92, 1926–1934 (2000).
  Article CAS Google Scholar
• Harris, R.E., Alshafie, G.A, Abou-Issa, H. & Seibert, K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60, 2101–2113 (2000).
  CAS PubMed Google Scholar
• Torrance, C.J. et al. Combinatorial chemoprevention of intestinal neoplasia using an NSAID and an EGFR-kinase inhibitor. Nature Med. 6, 1024–1028 (2000).
  Article CAS Google Scholar
• Vadlamui, R. et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18, 305–314 (1999).
  Article Google Scholar
• Hynes, N.E. & Stern, D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 119, 165–184 (1994).
  Google Scholar
• Perou, C.M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
  Article CAS Google Scholar
• Alizadeh, A.A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
  Article CAS Google Scholar
• Houston, S.J. et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer. 79, 1220–1226 (1999).
  Article CAS Google Scholar
• Sjogren, S., Inganas, M., Lindgren, A., Holmberg, L. & Bergh, J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J. Clin. Oncol. 16, 462–469 (1998).
  Article CAS Google Scholar
• Archer, S.G. et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer 72, 1259–1266 (1995).
  Article CAS Google Scholar
• Berns, E.M. et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159, 11–18 (1995).
  Article CAS Google Scholar
• Leitzel, K. et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 13, 1129–1135 (1995).
  Article CAS Google Scholar
• Nicholson, R.I. et al. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res. Treat. 29, 117–25 (1994).
  Article CAS Google Scholar
• Borg, A. et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81, 137–144 (1994).
  Article CAS Google Scholar
• Wright, C. et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer 65, 118–121 (1992).
  Article CAS Google Scholar
• Jarvinen, T.A., Holli, K., Kuukasjarvi, T. & Isola, J.J. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer 77, 2267–2273 (1998).
  Article CAS Google Scholar
• Rozan, S. et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer 79, 27–33 (1998).
  Article CAS Google Scholar
• Paik, S. et al., erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 90, 1361–1370 (1998).
  Article CAS Google Scholar
• Jacquemier, J. et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res. 14, 2773–2778 (1994).
  CAS PubMed Google Scholar
• Allred, D.C. et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol. 23, 974–979 (1992).
  Article CAS Google Scholar
• Gusterson, B.A. et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol 10, 1049–1056 (1992).
  Article CAS Google Scholar